Thomas Benedict is a Senior Scientific Lead at Eli Lilly and Company, specializing in protein expression, purification, and structural biology. With over five years of research experience in transcriptional regulation in cancer, Thomas has developed expertise in various laboratory techniques, including mammalian cell culture, transfection, and immunoblotting. Thomas earned a Bachelor's degree in Biochemistry and Molecular Biology from the University of California, Santa Cruz, followed by a PhD from the University of California, Riverside. Previously, Thomas worked as a Scientist in Structural Biology at Loxo Oncology at Lilly from 2021 to 2024.
This person is not in the org chart
This person is not in any teams
This person is not in any offices